Loading...
Chronic limb-threatening ischemia is the severest stage of peripheral artery disease (PAD) and is associated with nonhealing wounds, high risk of major lower-extremity (LE) amputation, and cardiovascular death. Lower-extremity revascularization (LER) and wound care are the principal limb-salvage therapies for chronic limb-threatening ischemia. AMG0001 is an investigational (not FDA-approved) plasmid containing human hepatocyte growth factor (HGF) cDNA. Researchers conducted this phase 2, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of 4-mg or 8-mg injections of AMG0001 in wound healing in 75 patients with PAD, mild-to-moderate foot ischemia, and neuroischemic LE ulcers, including at least one full-thick…